Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: Final report

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 3, 2009, Pages 311-319

  Dillman, Robert O ^a   Selvan, Senthamil R ^a   Schiltz, Patric M ^a   McClay, Edward F ^b   Barth, Neil M ^a   Depriest, Carol ^a   De Leon, Cristina ^a   Mayorga, Cheryl ^a   Cornforth, Andrew N ^a   Allen, Kanoe ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Melanoma Research Center of San Diego   (United States)

Author keywords

Dendritic cells; Metastatic melanoma; Tumor cell lines; Tumor stem cells; Vaccines

Indexed keywords

ALPHA INTERFERON; ANTIGEN; BCG VACCINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DACARBAZINE; DENDRITIC CELL VACCINE; DIPHENHYDRAMINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; NAVELBINE; NITROSOUREA; PARACETAMOL; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TUMOR MARKER; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS TUMOR CELL; BLOOD CELL; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CULTURE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HUMAN; HYPERMENORRHEA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SURVIVAL RATE; TUMOR CELL; URTICARIA; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES; ANTIGENS, CD; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; GANGLIOSIDES; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PHAGOCYTOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67650826075     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0599     Document Type: Article

References (28)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622.
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. NEJM 2004;351:998.
3. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65.
4. Dillman RO, Beutel LD, Barth NM, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002;17:51.
5. Dillman RO, Barth NM, VanderMolen LA, et al. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm 2004;19:570.
6. Dillman RO, Beutel LD, DePriest C, et al. Cancer vaccine potency: Is there a dose/response relationship for patient-specific vaccines and clinical outcomes? Cancer Biother Radiopharm 2005;20:373.
7. Dillman RO, DePriest C, DeLeon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;22:309.
8. Dillman RO, Selvan SR, Schlitz PM, et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: Planned interim analysis. Cancer Biother Radiopharm 2004;19:658.
9. Dillman RO, Selvan SR, Schlitz PM. Patient-specific dendritic cell vaccines for metastatic melanoma. NEJM 2006; 355:1179.
10. Selvan SR, Dillman RO, Fowler AW, et al. Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker. Internat J Cancer 2008;122:1374.
11. Schiltz PM, Dillman RO, Korse CM, et al. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells. Cancer Biother Radiopharm 2008;23:214.
12. Cornforth A, Selvan RS, Fowler A, et al. Immune monitoring during the course of adaptive immunotherapy using autol-ogous dendritic cells loaded with gamma-interferon treated, irradiated autologous tumor cells in patients with metastatic melanoma. Proc Am Assoc Cancer Res 2008;49:678. [Abstract 2865]
13. Cornforth AN, Lee GJ, Fowler AW, et al. Autologous dendritic cell immunotherapy-induced increases in serum tarc/ccl17 levels are associated with progression-free survival in advanced melanoma patients. International Society for Biological Therapy of Cancer 23rd Annual Meeting, San Diego, CA, October 30-November 2, 2008. J Immunother 2008;31:935.
14. Selvan SR, Carbonell DJ, Fowler AW, et al. Establishment of melanoma cell lines for autologus vaccine therapy: Comprehensive analysis of seven-year feasibility. International Society for Biological Therapy of Cancer 23rd Annual Meeting, San Diego, CA. November 1, 2008. J Immunother 2008;31:949.
15. Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527.
16. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007;25:474s. [Abstract 8508]
17. Sondak VK, Liu P-Y, Tuthill RJ, et al. Adjuvant immuno-therapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058.
18. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 2003;26:349.
19. Chapman PB, Williams L, Salibi N, et al. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 2004;22:2904.
20. Berd D. M-Vax: An autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 2004;3:521.
21. Slingluff CL, Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized, phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016.
22. Tagawa ST, Cheung E, Banta W, et al. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006;106:1353.
23. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. J Clin Oncol 2008;26:955.
24. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69.
25. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882.
26. Hersey P, Coates AS, McCarthy, et al. Adjuvant immuno-therapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol 2002;20:4181.
27. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003;13:401.
28. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon Alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007;25:2078.